Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized Controlled Trial in Guinea-Bissau.

Thursday, 19th of January 2017 Print

J Infect Dis. 2017 Jan 10. pii: jiw512. doi: 10.1093/infdis/jiw512. [Epub ahead of print]

Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized Controlled Trial in Guinea-Bissau.

Do VA12 Biering-Sørensen S12 Fisker AB12 Balé C2 Rasmussen SM12 Christensen LD12 Jensen KJ13 Martins C2 Aaby P2 Benn CS14.

Author information



 Children in Guinea-Bissau receive measles vaccine (MV) at 9 months of age but studies have shown that an additional dose before 9 months of age might have beneficial nonspecific effects. Within a randomized trial designed to examine nonspecific effects of early MV receipt on mortality we conducted a sub study to investigate the effect of early MV receipt on morbidity.


 Children were randomly assigned at a ratio of 2:1 to receive 2 doses of MV at 18 weeks and age 9 months (intervention group) or 1 dose of MV at age 9 months in accordance with current practice (control group). Children were visited weekly from enrollment to age 9 months; the mother reported morbidity and the field assistants examined the children. Using Cox and binomial regression models we compared the 2 randomization groups.


 Among the 1592 children early measles vaccination was not associated with a higher risk of the well-known adverse events of fever rash and convulsions within the first 14 days. From 15 days after randomization to age 9 months early measles vaccination was associated with reductions in maternally reported diarrhea (hazard ratio [HR] 0.89; 95% confidence interval [CI] .82-.97) vomiting (HR 0.86; 95% CI .75-.98) and fever (HR 0.93; 95% CI .87-1.00).


 Early MV receipt was associated with reduced general morbidity in the following months supporting that early MV receipt may improve the general health of children.


Special Postings


Highly Accessed

Website Views